A new clinical trial has been registered on the ClinicalTrials.gov
website. Researchers at the Johns Hopkins Kimmel Cancer Center, in collaboration with the National Cancer Institute, plan to compare outcomes of treatment with the chemotherapy agent docetaxel when given with or without intravenous ascorbic acid in treating patients with metastatic prostate cancer. According to the info posted, they intend to register 69 patients for this trial.
Douglas Q. Kitt, founder of ReCverin LLC, sellers of stabilized dehydroascorbic acid solutions.